Research Article - International Journal of Clinical Rheumatology (2019) Volume 14, Issue 2
Clinical presentation and management of idiopathic granulomatous mastitis in a Middle Eastern country-a case series
- Corresponding Author:
- Hanif UK
Department of Medicine, Birmingham Heartlands Hospital, UK
E-mail: [email protected]
Introduction: Idiopathic Granulomatous Mastitis (IGM) is a rare and benign inflammatory condition of the breast. IGM cases have been poorly documented in the Middle East, highlighting the need for improved awareness. Aim and Methods: A retrospective review of medical records was conducted, at a specialist centre on the clinical presentation, radiological findings, histopathological features, treatment and outcomes of IGM patients. Results: We identified twenty-two patients with a mean age of 36.6 years (range: 25-51) at presentation to breast clinic. 21/22 (96%) patients presented with a breast lump. 17/22 (77%) patients had breast pain, 4/22 (18%) patients had nipple discharge and 7/22 (32%) had palpable lymph nodes. GM was diagnosed histopathologically in 50% of fine needle aspirates, and 94% of core biopsies of breast. Conservative treatment was the sole treatment in 27%, while surgical management was undertaken in 5% of the patients. Conclusion: IGM appears to be a prevalent concern amongst Middle Eastern countries. There appears to be a diminishing role of surgery in its management and the role of immunosuppressants is emerging.
granulomatous • mastitis • breast • disease • Middle East
Idiopathic Granulomatous Mastitis (IGM) is a benign inflammatory condition of the breasts that predominantly affects parous, pre-menopausal women with a recent history of lactation [1-3]. It commonly presents as a unilateral painful mass associated with erythematous skin changes, abscess formation and axillary lymphadenopathy [1-5]. Clinically, it is often mistaken for inflammatory breast carcinoma, breast abscess and periductal mastitis and radiology is of limited value in differentiating it from other inflammatory and malignant diseases [1,2,6-11]. Diagnosis is confirmed by histopathological evaluation of breast tissue and can only be made clinically after the exclusion of sarcoidosis, Wegener’s granulomatosis, giant cell arteritis, polyarteritis nodosa, tuberculosis and parasitic and fungal infections [1-3,10,12,13].
Surgical excision and high dose corticosteroids remain the mainstay of treatment [9-10,14]. However, immunosuppressive therapy has recently been reported as an attractive alternative in reducing corticosteroid therapy and postoperative recurrence rates [1,15].
IGM is prevalent in the Middle East, despite a lack of awareness among health professionals [16-18]. There remains a paucity in the literature for IGM cases documented in the Middle East. Herein we retrospectively review and compare the clinical presentation, epidemiology and management of IGM in the United Arab Emirates (UAE) to better inform the diagnosis and treatment of this rare and important disease.
A retrospective review of twenty-two patients with a histopathological diagnosis of IGM was conducted at a specialist breast and rheumatology centre in the UAE. Clinical records were examined for clinical presentation, radiological findings, histopathological features, treatments and outcomes. Patients with incomplete clinical records were excluded from our cohort. The study was conducted in accordance to the principles of the Declaration of Helsinki.
Twenty-two female patients were identified and included in this study. Demographic details are outlined in Table 1 and obstetric history in Table 2.
|Ethnicity-Number of Patients (%)||Emirati-11 (50%)
Great Britain-1 (4.5%)
|Mean Age at Presentation (Range)||36.6 (35-51)|
Table 1. Patient demographic details.
|Component of Patient History||Patient Cohort Aggregated Details|
|Duration of Symptoms-Days (Range (Months))||45.6 (0-5)|
|Mean age of menarche-Years (Range)||12.9 (9-16)|
|Menopausal Status (%)-Premenopausal
|Mean Age (Years) of 1st Pregnancy (Range)||25.14 (19-33)|
|Mean Parity||3.09 (1-9)|
|Previous/Current Use of Contraception (%)
Oral Contraceptive Pill
|Previous Breast-Feeding (%)||22 (100%)|
|History of Previously Diagnosed Cancer (%)||0 (0%)|
Table 2. Patient obstetric details.
The most common presenting complaints were a palpable breast mass (21/22; 96%), mastalgia (17/22; 77%), skin changes (11/22; 50%) and palpable axillary lymph nodes (7/22; 32%). Only one patient reported mastalgia alone. There was no difference in the distribution of masses between the right and left breasts. A single patient presented with bilateral breast masses. Locations by quadrant are outlined in Table 3. Sixteen (73%) patients reported noncyclical pain and one (4.5%) reported cyclical pain. Left-sided axillary lymphadenopathy was palpable in 3 (14%) cases and right-sided axillary lymphadenopathy was palpated in 3 (14%) cases. One (4.5%) patient presented with bilaterally palpable axillary lymph nodes. Ten (45%) patients reported erythematous skins changes, 4 (18%) nipple discharge and 3 (14%) had a clinical impression of breast abscess at presentation. Erythema nodosum (1/22; 4.5%) and an inflammation of the right nipple (1/22; 4.5%) were also documented.
|Outer Upper||7 (29)|
|Outer Lower||5 (21)|
|Inner Upper||4 (17)|
|Central and Inner Lower||3 (12)|
|Twelve o’clock position||2 (8)|
Table 3. Location (by quadrant) of Breast Masses.
Imaging and histopathology
Ultrasonography was performed in 18/22 patients (82%). Only 12 of the 18(67%) found hypoechoic vascularised lesions, with the remaining finding no clinically significant pathology. Eight (36%) patients underwent mammography. An ill-defined mass was identified in 3/8 (38%) instances and an asymmetric density with irregular margins in a further 2/8 (25%). Peri-areolar ductal dilatation (12.5%), bilateral axillary lymphadenopathy (12.5%) and benign lymphadenopathy (12.5%) were also reported. No mammography was undertaken in 13/22 (59%) patients.
Twelve (54%) patients underwent fine needle aspiration cytology (FNAC). The results were reported as IGM in five (42%) patients. Other diagnoses included ‘abscess’ in six (50%) patients (50%), and ‘IGM with abscess’ in one (8%) patient. Of the five (23%) patients who underwent open biopsy, three received a diagnosis of IGM alone; the remaining two patients received a diagnosis of ‘IGM with abscess’. Sixteen patients underwent core biopsy, diagnosing IGM in twelve (75%) patients, ‘abscess alone’ in one (6%) patient and ‘IGM with abscess’ in three (19%) patients.
Histopathological evaluation followed FNAC, open and core biopsies. All cases showed evidence of epithelioid non-caseating granulomatous inflammation. There was a varying degree of infiltration of Langerhans multinucleated giant cells, neutrophils, lymphocytes, plasma and other inflammatory cells around mammary lobules.
Seventeen patients (77%) of the cohort were treated with antibiotics and thirteen patients (59%) were treated with non steroid antiinflammatories (NSAIDs). Conservative therapy alone was defined as treatment with antibiotics and/or NSAIDs. Treatment strategies using steroid therapy, Disease Modifying Anti- Rheumatic Diseases (DMARDs) and surgical approaches(lumpectomy/incision and drainage) are listed in Table 4. Methotrexate was the DMARD prescribed, and Prednisolone the corticosteroid of choice. Recurrence rate of 36% was calculated in our cohort.
|Treatment Strategies||Frequency (%)|
|Surgery Alone||1 (5)|
|Steroids Alone||6 (27)|
|Methotrexate Alone||1 (5)|
Table 4. Treatment Strategies.
There are few reports in the literature documenting IGM cases in the Middle East [17-20]. Our study identified 22 patients, at a specialist rheumatology centre in the UAE. Thirteen (59%) were documented as being indigenous to an Arab nation (11 Emiratis, 1 Lebanese and 1 Jordanian). Clinically, our cohort reported palpable breast masses (96%) and mastalgia (77%) as the most common presenting complaints and FNAC (54%), core biopsy (73%) and ultrasonography (82%) were routinely used to facilitate diagnosis. Conservative management and prednisolone alone were recorded as the most common therapeutic approaches in our study.
The underlying aetiology is poorly understood . Kessler and Wolloch first proffered an autoimmune cause, noting histopathological consistencies between IGM, granulomatous thyroiditis and orchitis- later widely supported following IGM’s response to corticosteroids [2,5,6,9,10]. Other studies proposed associations of IGM to hormonal imbalances secondary to the use of the Oral Contraceptive Pill (OCP), breastfeeding, hyperprolactinemia, a-1 antitrypsin deficiency and local granulomatous immune responses to irritants, trauma and infections [8,9,21-23]. Although our data made no attempt at identifying autoimmune diagnoses; all females reported previous breastfeeding, most were pre-menopausal and 5 (23%) reported the use of the OCP.
Breast lumps and mastalgia are frequently identified as the most common clinical presentations – findings that are consistent with our centre’s experience [1-5,15-19]. Our cohort also demonstrated erythematous skin changes (45%), palpable axillary lymph nodes (32%) and nipple discharge (18%), which are well documented in the literature [1,7,15,16]. Other studies have reported cases of nipple bleeding and fistulation [17,18].
Diagnosis by histopathological evaluation is considered the gold standard [13,24]. It is characterised by the presence of non-caseating granulomas with epithelioid histiocytes in a predominantly neutrophilic background, limited to the mammary lobules with frequent microabscesses [2,3,10,12,25]. All cases of histopathological evaluation demonstrated epithelioid non-caseating granulomatous inflammation, in our cohort. Radiological modalities are limited in their diagnostic ability and in differentiating IGM from malignant disease [14,24]. Commonly reported findings include axillary lymphadenopathy, asymmetric and poorly-outlined lesions, and parenchymal distortion on mammography [9,24]. Ultrasound findings extend to hypoechoic masses and thickened skin . There is a suggestion that a complete triple assessment can facilitate satisfactory distinction of an IGM lesion from a malignancy .
Management approaches include conservative management, antibiotics, immunosuppressants, corticosteroids and surgical excision [1-3,8-10,12,14,16,24]. Conservative therapy constitutes a watch-and-wait approach, in the absence of any surgical or medical intervention . Surgical excision and high dose corticosteroids are the preferred therapeutic strategies [9-10,14]. Immunosuppressant such as methotrexate, hydroxychloroquine and colchicine may, however, be attractive alternatives [15,17-20,26].
In summary, our study demonstrated that IGM presents with breast lumps and associated pain and that histopathological evaluation of lesions facilitated diagnoses. Prednisolone use and conservative measures were the most commonly used treatment approaches. Importantly, IGM is prevalent in the Middle-East, despite the poor awareness amongst healthcare practitioners. Of interest is that 55% of our cohort was Emirati, who only constitute 11% of the UAE population. This may be skewed by the patient profile enrolled at this specific breast centre. The role of immunosuppressive is developing, leading to rheumatological input (from centre’s like ours) into multi-disciplinary teams becoming increasingly important.
- Kok KY, Telisinghe PU. Granulomatous mastitis: presentation, treatment and outcome in 43 patients. Surgeon. 8(4), 197–201 (2010).
- Al-Khaffaf B, Knox F, Bundred NJ. Idiopathic granulomatous mastitis: a 25-year experience. J. Am. Coll. Surg. 206(2), 269–273 (2008).
- Patel RA, Strickland P, Sankara IR et al. Idiopathic granulomatous mastitis: case reports and review of literature. J. Gen. Intern. Med. 25(3), 270–273 (2010).
- Diesing D, Axt-Fliedner R, Hornung D et al. Granulomatous Mastitis. Arch. Gynecol. Obstet. 269(4), 233–236 (2004).
- Kessler E, Wolloch Y. Granulomatous mastitis: a lesion clinically simulating carcinoma. Am. J. Clin. Pathol. 58(6), 642–646 (1972).
- Akahane K, Tsunoda N, Kato M et al. Therapeutic strategy for granulomatous lobular mastitis: a clinicopathological study of 12 patients. Nagoya. J. Med. Sci. 75(3-4), 193–200 (2013).
- Olsen ML, Dilaveri CA. Idiopathic granulomatous mastitis: a case report of breast abscess. BMJ. Case. Reports. (2011).
- Akcan A, Akyildiz H, Deneme MA et al. Granulomatous lobular mastitis: a complex diagnostic and therapeutic problem. World. J. Surg. 30(8), 1403–1409 (2006).
- Larsen HLJ, Peyvandi B, Klipfel N et al. Granulomatous lobular mastitis: imaging, diagnosis, and treatment. Am. J. Roentgenol. 193(2), 574–581 (2009).
- Kim J, Tymms KE, Buckingham JM. Methotrexate in the management of granulomatous mastitis. ANZ. J. Surg. 73(4), 247–249 (2003).
- Yip CH, Jayaram G, Swain M. The value of cytology in granulomatous mastitis: a report of 16 cases from Malaysia. ANZ. J. Surg. 70(2), 103–105 (2000).
- Akbulut S, Yilmaz D, Bakir S. Methotrexate in the management of idiopathic granulomatous mastitis: review of 108 published cases and report of four cases. Breast. J. 17(6), 661–668 (2011).
- Ocal K, Dag A, Turkmenoglu O et al. Granulamatous Mastitis: Clinical, Pathological Features, and Management. Breast. J. 16(2), 176–182 (2010).
- Azlina AF, Ariza Z, Arni T et al. Chronic granulomatous mastitis: diagnostic and therapeutic considerations. World. J. Surg. 27(5), 515–518 (2003).
- Neel A, Hello M, Cottereau A et al. Long-term outcome in idiopathic granulomatous mastitis: a western multicentre study. QJM. 106(5), 433–441 (2013).
- Baslaim MM, Khayat HA, Al-Amoudi SA. Idiopathic granulomatous mastitis: a heterogeneous disease with variable clinical presentation. World. J. Surg. 31(8), 1677–1681 (2007).
- Venkatramana M, Sharma PK, Jassim G et al. Profile of patients with idiopathic granulomatous mastitis presenting to a university teaching hospital in UAE: A case series. Int. J. Med. Sci. Public. Health. 3(3), 173–175 (2013).
- Omranipour R, Mohammadi SF, Samimi P. Idiopathic granulomatous lobular mastitis - report of 43 cases from iran; introducing a preliminary clinical practice guideline. Breast. Care (Basel). 8, 439–443 (2013).
- Aldaqal SM. Idiopathic Granulomatous Mastitis: Clinical presentation, radiological features and treatment. Saudi. Med. J. 25(12), 1884–1887 (2004).
- Al-Nazer MA. Idiopathic granulomatus lobular mastitis. A forgotten clinical diagnosis. Saudi. Med. J. 24(12), 1377–1380 (2003).
- Altinoprak F, Kivilcim T, Ozkan OV. Aetiology of idiopathic granulomatus mastitis. World. J. Clin. Cases. 2(12), 852–858 (2014).
- Lin CH, Hsu CW, Tsao TY et al. Idiopathic granulomatous mastitis associated with risperidone-induced hyperprolactinemia. Diagn. Pathol. 7(2) (2012).
- Schelfout K, Tjalma WA, Cooremans ID et al. Observations of an idiopathic granulomatous mastitis. Eur. J. Obstet. Gynecol. Reprod. Biol. 97, 260–262 (2001).
- Lai EC, Chan WC, Ma TK et al. The role of conservative treatment in idiopathic granulomatous mastitis. Breast. J. 11(6), 454–456 (2005).
- Gurleyik G, Aktekin A, Aker F et al. Medical and surgical treatment of idiopathic granulomatous lobular mastitis: a benign inflammatory disease mimicking invasive carcinoma. J. Breast. Cancer. 15(1), 119–123 (2012).